Merck & Co., Inc. provided earnings guidance for the full year 2025. For the period, the company anticipates full-year sales to be between $64.1 billion and $65.6 billion, including a negative impact of foreign exchange of approximately 2% at mid-January 2025 exchange rates.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
88.05 USD | -1.81% |
|
-11.02% | -11.49% |
Feb. 06 | Trump faces pressure from US industry over China tariff on medicines | RE |
Feb. 06 | Merck Initiates Phase 3 Trial of Zilovertamab Vedotin Antibody-Drug Conjugate to Treat Lymphoma | MT |

Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Merck & Co., Inc. Provides Earnings Guidance for the Full Year 2025